NASDAQ:INCYIncyte Stock Price, Forecast & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INCY shares have increased by 31.9% and is now trading at $94.87.
View which stocks have been most impacted by COVID-19.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Incyte.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) announced its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported $1.04 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.36. The biopharmaceutical company earned $688 million during the quarter, compared to analysts' expectations of $617.55 million. Incyte had a negative return on equity of 8.06% and a negative net margin of 8.00%. The business's revenue for the quarter was up 29.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.75 earnings per share.
View Incyte's earnings history.

23 brokerages have issued 12 month target prices for Incyte's stock. Their forecasts range from $83.00 to $124.00. On average, they anticipate Incyte's share price to reach $102.30 in the next year. This suggests a possible upside of 7.8% from the stock's current price.
View analysts' price targets for Incyte.

Press coverage about INCY stock has trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Incyte earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Incyte.

Incyte saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 4,530,000 shares, an increase of 14.7% from the December 31st total of 3,950,000 shares. Based on an average trading volume of 1,410,000 shares, the short-interest ratio is currently 3.2 days. Approximately 2.1% of the shares of the stock are short sold.
View Incyte's Short Interest.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Kite Pharma (KITE), Freeport-McMoRan (FCX) and Array Biopharma (ARRY).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.48%), Bellevue Group AG (1.51%), First Trust Advisors LP (0.89%), California Public Employees Retirement System (0.71%), Bank of New York Mellon Corp (0.65%) and Sumitomo Mitsui Trust Holdings Inc. (0.42%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, State of Tennessee Treasury Department, UBS Group AG, Bank of Nova Scotia, Country Trust Bank, Sector Gamma AS, Sumitomo Mitsui Trust Holdings Inc., and Russell Investments Group Ltd.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing.
View insider buying and selling activity for Incyte.

INCY stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, First Trust Advisors LP, TD Asset Management Inc., NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., FMR LLC, Epoch Investment Partners Inc., and Vanguard Group Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime.
View insider buying and selling activity for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $94.87.

Incyte has a market capitalization of $20.75 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]